SEP 14, 2026 · JOURNAL ARTICLE
The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer
Clinical Cancer Bulletin
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. More than 80% of patients are diagnosed at an advanced stage, and the 5‑year survival rate rem